EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
EyePoint, Inc. (EYPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments – Organizational focus on DURAVYU TM Phase 3 DME program; trials fully enrolled with topline data expected in early Q4 2027 – – DURAVYU DME program supported by the posit
How this was made
The 30-second read
Why it matters
The mixed clinical data introduces uncertainty; investors will likely reassess valuation multiples for the company and its peers.
Market read
First‑time disclosure of pivotal trial results makes this filing highly relevant for traders in biotech and ophthalmology sectors.
What to watch
Cash runway of $118 M and upcoming Q4 2027 topline data may provide runway for a turnaround.
EyePoint reports Q3 2026 net loss of $(95,612) thousand, or $(1.07) per share, as Phase 3 wet AMD program is concluded and workforce is cut about 53%
Total revenues were $756 thousand against $966 thousand a year earlier, operating expenses rose to $97,633 thousand from $62,991 thousand, and the company reports cash, cash equivalents and marketable securities of $118 million. The Phase 3 LUGANO and LUCIA wet AMD trials did not achieve their primary endpoints, the wet AMD program is being wound down, and the filing states the cash runway extends only into late third quarter of 2027, with going-concern uncertainty listed among risks.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenues (three months ended Sept 30, 2026)GAAP | $756K | – | – |
| Product sales, net (three months)GAAP | $528K | – | – |
| License and collaboration agreements (three months)GAAP | $49K | – | – |
| Royalty income (three months)GAAP | $179K | – | – |
| Cost of sales (three months)GAAP | $523K | – | – |
| Research and development (three months)GAAP | $81.67M | – | – |
| Sales and marketing (three months)GAAP | $31K | – | – |
| General and administrative (three months)GAAP | $15.41M | – | – |
| Total operating expenses (three months)GAAP | $97.63M | – | – |
| Loss from operations (three months)GAAP | −$96.88M | – | – |
| Interest and other income, net (three months)GAAP | $1.26M | – | – |
| Net loss before provision for income taxes (three months)GAAP | −$95.61M | – | – |
| Provision for income taxes (three months)GAAP | — | – | – |
| Net loss (three months)GAAP | −$95.61M | – | – |
| Net loss per common share, basic and diluted (three months)GAAP | $(1.07) | – | – |
| Total revenues (nine months ended Sept 30, 2026)GAAP | $1.96M | – | – |
| Product sales, net (nine months)GAAP | $995K | – | – |
| License and collaboration agreements (nine months)GAAP | $695K | – | – |
| Royalty income (nine months)GAAP | $269K | – | – |
| Cost of sales (nine months)GAAP | $1.06M | – | – |
| Research and development (nine months)GAAP | $237.4M | – | – |
| Sales and marketing (nine months)GAAP | $65K | – | – |
| General and administrative (nine months)GAAP | $44.89M | – | – |
| Total operating expenses (nine months)GAAP | $283.4M | – | – |
| Loss from operations (nine months)GAAP | −$281.5M | – | – |
| Interest and other income, net (nine months)GAAP | $6.52M | – | – |
| Net loss before provision for income taxes (nine months)GAAP | −$275.0M | – | – |
| Provision for income taxes (nine months)GAAP | $50K | – | – |
| Net loss (nine months)GAAP | −$274.9M | – | – |
| Net loss per common share, basic and diluted (nine months)GAAP | $(3.15) | – | – |
| Cash, cash equivalents and marketable securities (as of Sept 30, 2026)other | $118M | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Product sales, netNo driver stated in the filing. | $528K | – | – |
| License and collaboration agreementsNo driver stated in the filing. | $49K | – | – |
| Royalty incomeNo driver stated in the filing. | $179K | – | – |
Capital returns
- No share repurchases or dividends are reported in the filing.
- The filing states that the company raised an additional $10 million after quarter-end under its at-the-market equity facility.
What drove it
- The company attributes the increase in operating expenses for the quarter primarily to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME.
- Research and development expense for the quarter was $81,670 thousand compared with $47,754 thousand a year earlier.
- Following the LUCIA results, the Board approved a strategic prioritization focused on the late-stage DME program, with an approximately 53% workforce reduction and associated operational adjustments.
- The company estimates these actions will generate approximately $30 million in annualized savings.
- Phase 3 LUGANO (announced August 17, 2026) did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population.
- Phase 3 LUCIA (announced October 19, 2026) did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population.
- The company will conclude the wet AMD program before completion of the full second year of the Phase 3 LUGANO and LUCIA studies, while allowing additional patients to complete year two to support the safety database for a potential DME new drug application.
- Phase 3 COMO and CAPRI DME trials are reported as fully enrolled with over 550 patients, with topline data expected early in the fourth quarter of 2027.
Concerns
- Net loss widened to $(95,612) thousand from $(59,732) thousand, and nine-month net loss was $(274,914) thousand against $(164,353) thousand.
- Revenue is minimal: total revenues were $756 thousand for the quarter and $1,959 thousand for the nine months, against $30,751 thousand in the prior-year nine months, which included license and royalty income.
- Cash, cash equivalents and marketable securities fell to $118 million from $306 million at December 31, 2025, and the company reports a cash runway only into late third quarter of 2027.
- The forward-looking statements section lists uncertainty regarding the company's ability to continue as a going concern.
- The forward-looking statements section lists the company's ability to comply with Nasdaq's minimum bid compliance requirement as a risk.
- The forward-looking statements section lists uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.
- The company may incur additional costs in connection with its strategic prioritization not currently contemplated, according to the forward-looking statements section.
What to watch
- Topline data from Phase 3 COMO and CAPRI DME trials, expected early in the fourth quarter of 2027.
- Execution of the workforce reduction and whether the approximately $30 million annualized savings are realized as estimated.
- Progress on business development, financing and other cost reduction opportunities that the company says could extend the cash runway.
- Additional analyses of LUGANO, LUCIA and pooled Phase 3 data, which the company says will assess next steps for wet AMD.
- Use of the at-the-market equity facility following the additional $10 million raised after quarter-end.
- Resolution of the FDA warning letter relating to the Watertown, MA manufacturing facility.
- Nasdaq minimum bid compliance status.
Balance sheet and cash flow
- Cash, cash equivalents and marketable securities were $118 million as of September 30, 2026, compared with $306 million as of December 31, 2025.
- Balance sheet at September 30, 2026: cash and cash equivalents $83,206 thousand; marketable securities $35,007 thousand; total current assets $126,986 thousand; total assets $166,137 thousand; total liabilities $57,631 thousand; total stockholders' equity $108,506 thousand.
- Balance sheet at December 31, 2025: cash and cash equivalents $101,821 thousand; marketable securities $204,265 thousand; total assets $363,996 thousand; total stockholders' equity $306,113 thousand.
- The company states that cash at September 30, 2026, together with the additional $10 million raised after quarter-end under its at-the-market facility and anticipated operational adjustments, will enable it to fund operations into late third quarter of 2027.
- The company states it continues to pursue business development, financing and other cost reduction opportunities that could further extend the cash runway.
- No operating cash flow or free cash flow figures are reported in the filing.
Analysis
EyePoint reported a third quarter 2026 GAAP net loss of $(95,612) thousand, or $(1.07) per share, against a net loss of $(59,732) thousand, or $(0.85) per share, a year earlier. Total revenues were $756 thousand, compared with $966 thousand, and the three product and royalty lines in the statement of operations were each lower than in the prior-year quarter. Operating expenses rose to $97,633 thousand from $62,991 thousand. Research and development expense accounts for most of the increase, moving to $81,670 thousand from $47,754 thousand, and the company attributes the rise primarily to the ongoing DURAVYU Phase 3 trials for wet AMD and DME. General and administrative expense was $15,409 thousand against $14,490 thousand.
The nine-month figures show the same pattern at a larger scale. Nine-month total revenues were $1,959 thousand against $30,751 thousand, and the prior-year period included license and collaboration revenue of $16,531 thousand and royalty income of $12,923 thousand, which were $695 thousand and $269 thousand in 2026. Nine-month research and development expense reached $237,427 thousand against $161,825 thousand, and the nine-month net loss was $(274,914) thousand. The filing does not print a gross margin figure, and cost of sales is reported as a line item only.
The balance sheet shows cash, cash equivalents and marketable securities of $118 million at September 30, 2026, against $306 million at December 31, 2025. Total stockholders' equity fell to $108,506 thousand from $306,113 thousand. The company states that this balance, together with a further $10 million raised after quarter-end under its at-the-market facility and anticipated operational adjustments, will fund operations into late third quarter of 2027. The filing reports no share repurchases or dividends.
The filing's central disclosures concern the clinical program. The Phase 3 LUGANO trial in wet AMD (August 17, 2026) and the Phase 3 LUCIA trial (October 19, 2026) each did not meet the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population. The company will conclude the wet AMD program before the full second year of both studies and has moved resources to the DME program, where Phase 3 COMO and CAPRI are fully enrolled with over 550 patients and topline data are expected early in the fourth quarter of 2027. The company estimates the workforce reduction of about 53% will produce roughly $30 million in annualized savings. The CFO states that the company intends to pursue further levers to extend its financial runway.
For the reader, the points that merit attention are the narrow cash runway relative to the timing of DME topline data, the going-concern uncertainty and Nasdaq minimum bid compliance that the forward-looking statements section lists as risks, and the FDA warning letter tied to the Watertown facility. The filing gives no guidance figures, so there is no outlook to compare against.
Management, verbatim
“Capital discipline is now one of our highest priorities,”
George O. Elston, Executive Vice President and Chief Financial Officer
The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing.
Jay S. Duker, M.D., President and Chief Executive Officer
Not in the filing
stated, not guessed- Gross margin percentage is not printed in the filing.
- Percentage changes year over year for revenue, operating expenses and net loss are not printed.
- Prior-quarter (Q2 2026) figures are not printed in the filing.
- Segment-level prior-year and prior-quarter revenue figures are not printed.
- Operating cash flow and free cash flow are not reported.
- Financial guidance figures are not provided; the filing gives only a cash runway statement.
- Prior-period outlook was not provided, so no guidance comparison is possible.
- Prior-year and prior-quarter comparison for cash, cash equivalents and marketable securities on a quarter basis is not printed; the $306 million comparison is as of December 31, 2025.
- Repurchases and dividends are not reported.
- Amount of the at-the-market facility and the terms of the $10 million raise are not printed beyond the stated amount.
- Share price reaction and analyst consensus estimates are not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
EyePoint's 8‑K combines quarterly financials with detailed updates on its lead product DURAVYU, covering both diabetic macular edema and wet age‑related macular degeneration programs.
Ticker impact
EyePoint filed its 8‑K reporting Q3 2026 results, announcing $118 M cash and new data on its DURAVYU program, including Phase 3 DME enrollment and mixed Phase 3 wet‑AMD outcomes.
potential modest downside pressure as investors weigh the wet‑AMD trial miss against DME progress
The filing is the first public disclosure of the trial results; the negative wet‑AMD data is material and likely to trigger sell‑side reactions, while the positive DME data offers some support.
Market effects
Highlights the risk/reward profile of retinal‑disease biotech firms and may affect peer valuations.
Limited to U.S. biotech sector; no broader regional effect.
Relevant to global investors tracking ophthalmology drug pipelines.
Counterpoint
The DME program's potential could outweigh the wet‑AMD setback, presenting a buying opportunity.
Key entities
- companyEyePoint, Inc.
Nasdaq‑listed developer of retinal‑disease therapeutics.
